Member Info for Soupdragon78

I get the feeling Dan always had the aim of getting the large deal signed as described in the company prospectus. He was confident this would happen in Q1 2020 and probably had a planned exit for then anyway. Just the timings didn't work out.

The lack of thanks for DG from Blackwell in some of the statements are probably because he wasn't too happy that he had to step into the void and do some work.

DT I think played fast and loose and got caught out, but I'll leave that for those on here who have contact with him to comment.

Indeed, the fact that Justin Waite not only buys/sells the shares he interviews without informing the market till later, but is also a director of Vox Markets Ltd tells you its all about lining their own pockets.

As its Baltic out there, staying in having a dig around as to what Oxilio might be up to with NXP001.

It seems they have a patent pending for "Use of NK-1 antagonists for the treatment of cancer", there's not description available (yet) so its a bit of guesswork.

https://patents.google.com/patent/GB201917862D0/en?assignee=Oxilio+Ltd&sort=new

So, what is a NK-1 antagonist, it would appear that there are a number of known drugs that fall into this category and are used to mitigate emesis as a result of chemotherapy.

"Neurokinin-1 receptor (NK-1) antagonists such as aprepitant, rolapitant, casopitant, fosaprepitant, netupitant, and maropitant are effective to treat postsurgical nausea and vomiting, and cancer chemotherapy-induced nausea and vomiting. "

The key item in the above is 'aprepitant' which is the clinical name for EMEND, which is the basis of NXP001, and which the NFX drug outperforms.

Now, the interesting bit. There has been previous research that has established a link between NK-1 receptors and Gastrointestinal Cancer (GI), specifically

https://bit.ly/2LUTFIm

"NK-1 receptor antagonists could be considered as a new generation of antitumor drugs against GI cancer.... because the drug is currently used in clinical practice for the treatment of emesis and hence the required safety for this drug has already been carried out. It seems that by increasing the number of days on which aprepitant is currently administered in clinical practice (three days), and using higher doses (because tumor cells overexpress the NK-1 receptor) than those used for chemotherapy-induced nausea and vomiting, aprepitant could be effective in the treatment of GI cancer."

So, Oxilio may be seeking to follow this path with NXP001 which has already been through human clinical trials showing bioequivalence to EMEND.

Good old Zak with his Grand Old Duke of York approach. “If it’s going up it’s going up....”

Still needs news to get it moving. Regardless of the charts.

I would argue the opposite, an options agreement on NXP001, discussions on NXP002, further preclinical on NXP002 for both IPF and possible Covid treatment. New ip development on NXP004 for multi billion oncology indication drug, plus preclinical data assessement for anti fibrotic and anti inflammatory.
Add to that Ebers rto. Which should see a resurgence in their activity.

Filter, I get that but it’s not such an issue. After all shareholders didnt say anything when nxp003 was dropped.

Not worth getting hung up on Vistagen, they’ve been paid for the work so if it hasn’t been successful then so be it.

They’re hardly going to flag up if it’s not successful as that would hammer the sp again.

Aberdeenman, with respect, the stock market through history is littered with examples of CEO’s who can give the patter and appear ‘competent’ only for it to be a load of flannel.

Results speak louder than countless interviews that don’t say much but appease shareholders.

Thompi, re-read the interims, you’ll find they actually hold more than you knew before.

Personally don’t see any point in introductions etc.

The interims gave a clear update as to what is happening. Until there is any news to report then there isn’t much point talking to the market.

I’d rather they are getting on with their work than holding short term pi’s hands.

The response can be read a couple of ways, the pessimistic is that they are not doing anything other than reviewing (again) or the positive that Brindley is "currently working with the team on the strategic priorities for the Group"

I think the use of the word 'review' will relate to items such as NXP004 which as the interims showed has two distinct directions now. They are reviewing the anti-inflammatory / anti-fibrotic results of the pre-clinical work. Also they have found it could potentially improve a successful multi-billion dollar drug, so they are reviewing the IP on that direction.

So two separate items to review as a strategic priority.

Sorry Chab, nothing much I can find, they are fairly anonymous at the moment.

Probably the most interesting thing I could find was that Ralph Browning has been involved in Saudi financing for most of his career.

At least they are on a six month option which will end in March, so we will find out more sooner rather than it drag on.

I wish they had done something similar with the Asia negotiations, especially if they were in talks with multiple parties, even a small company then has a card to play saying they won't wait forever to close the deal.

Only last month they said they would update in Q1, we are only two weeks into that period.

Not competition but will be good to see positive results as it will back up what use of tranilast as a Covid treatment.

In theory the results of this study should be around the end of this month.

http://www.chictr.org.cn/showprojen.aspx?proj=49738

If you were so worried then you’d easily be able to name the company you think is trying to squash nfx.

HIHopes, you wrote you didn’t know which company. All I’m saying is you could have found this info in the time you wrote your long text. Why didn’t you bother?

Red rag, seems a standard paragraph to me. The company were open to and answered questions at the last agm.

Anyway, Dr Anne Brindley has been busy, she's started the year by setting up her own real estate company.

HiHopes, so you can remember that 'all' of the new board members worked for the same company, yet you cannot remember which company that is? Nor can you spend 10 seconds even looking it up?

Come on son. If you are going to try and start a conspiracy theory you need to sound convincing.

Thanks TR64, maybe ask MD.J.Morgan about Leverett and Ingelheim, he was big into that scene last year.